---
title: "Vertex Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293518578.md"
description: "Vertex Pharmaceuticals (VRTX) shares fell 1.96% to $472.57 on Wednesday, underperforming competitors like AbbVie and Krystal Biotech during a broader market decline. The stock closed 11.45% below its 52-week high. Trading volume was below the 50-day average."
datetime: "2026-07-22T20:36:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293518578.md)
  - [en](https://longbridge.com/en/news/293518578.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293518578.md)
---

# Vertex Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Vertex Pharmaceuticals Inc. (VRTX) shed 1.96% to $472.57 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 0.14% to 7,498.96 and Dow Jones Industrial Average falling 0.01% to 52,218.58.

Vertex Pharmaceuticals Inc. closed 11.45% below its 52-week high of $533.67, which the company reached on July 7th.

The stock underperformed when compared to some of its competitors Wednesday, as AbbVie Inc. (ABBV) fell 1.09% to $253.30, Krystal Biotech Inc. (KRYS) fell 0.67% to $336.80, and Arcturus Therapeutics Holdings Inc. (ARCT) fell 1.00% to $5.93.

Trading volume (1.3 M) remained 308,849 below its 50-day average volume of 1.6 M.

Data source: Dow Jones Market Data, FactSet. Data compiled July 22, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

07-22-26 1636ET

### Related Stocks

- [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md)
- [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md)
- [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md)
- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)
- [KRYS.US](https://longbridge.com/en/quote/KRYS.US.md)
- [ARCT.US](https://longbridge.com/en/quote/ARCT.US.md)

## Related News & Research

- [Vertex Pharmaceuticals Inc Stock (VRTX) Opened Up by 9.76% on Aug 10: What Investors Need To Know](https://longbridge.com/en/news/295417036.md)
- [Could 1 tiny biotech topple Vertex Pharmaceuticals' cystic fibrosis empire?](https://longbridge.com/en/news/295269038.md)
- [VRTX: Q2 2026 revenue up 12% to $3.33B; full-year guidance raised; Crinetics acquisition pending](https://longbridge.com/en/news/294732107.md)
- [Entrada Therapeutics publishes corporate presentation on genetic medicines pipeline for neuromuscular and inherited retinal diseases](https://longbridge.com/en/news/294966190.md)
- [Vertex Stock Jumps 5.9% as Rival Cystic Fibrosis Drug Fails](https://longbridge.com/en/news/295428760.md)